Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Equity Average (2016 - 2025)

Plus Therapeutics has reported Equity Average over the past 15 years, most recently at $4.5 million for Q4 2025.

  • Quarterly Equity Average rose 164.08% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 164.08% year-over-year, with the annual reading at -$2.5 million for FY2025, 51.9% up from the prior year.
  • Equity Average was $4.5 million for Q4 2025 at Plus Therapeutics, up from $4.0 million in the prior quarter.
  • Over five years, Equity Average peaked at $13.4 million in Q3 2021 and troughed at -$16.3 million in Q1 2025.
  • The 5-year median for Equity Average is $4.3 million (2025), against an average of $2.9 million.
  • Year-over-year, Equity Average soared 907.55% in 2021 and then plummeted 1208.56% in 2024.
  • A 5-year view of Equity Average shows it stood at $12.8 million in 2021, then plummeted by 30.25% to $8.9 million in 2022, then plummeted by 92.86% to $637000.0 in 2023, then plummeted by 1208.56% to -$7.1 million in 2024, then surged by 164.08% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Equity Average are $4.5 million (Q4 2025), $4.0 million (Q3 2025), and -$10.3 million (Q2 2025).